{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:18:34Z","timestamp":1790990314675,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["520,151"],"award-info":[{"award-number":["520,151"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003579","name":"University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003579","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032850","name":"EU4Health","doi-asserted-by":"publisher","award":["101,127,787"],"award-info":[{"award-number":["101,127,787"]}],"id":[{"id":"10.13039\/100032850","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijantimicag.2025.107614","type":"journal-article","created":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T22:22:36Z","timestamp":1757197356000},"page":"107614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cross-border dialogue: An international survey of regulators on phage therapy"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6996-7638","authenticated-orcid":false,"given":"Riley D.","family":"Alvarez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"\u00c5rdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2905-5139","authenticated-orcid":false,"given":"Annika Y.","family":"Classen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobi E.","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter-Jan","family":"Ceyssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9983-7593","authenticated-orcid":false,"given":"Greg J.","family":"German","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2025.107614_bib0001","doi-asserted-by":"crossref","first-page":"987","DOI":"10.46234\/ccdcw2021.241","article-title":"World antimicrobial awareness week 2021 \u2014 Spread awareness, stop resistance","volume":"3","author":"Wu","year":"2021","journal-title":"China CDC Wkly"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0002","unstructured":"World Health Organization. Building evidence for the use of bacteriophages against antimicrobial resistance, https:\/\/www.who.int\/europe\/news\/item\/25-06-2024-building-evidence-for-the-use-of-bacteriophages-against-antimicrobial-resistance; 2024 [accessed 25 March 2025]."},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0003","unstructured":"Directive - 2001\/83 - EN - EUR-Lex, https:\/\/eur-lex.europa.eu\/eli\/dir\/2001\/83\/oj\/eng; 2021 [accessed 25 March 2025]."},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0004","doi-asserted-by":"crossref","first-page":"244","DOI":"10.5582\/irdr.2016.01054","article-title":"An overview of compassionate use programs in the European Union member states","volume":"5","author":"Balasubramanian","year":"2016","journal-title":"Intractable Rare Dis Res"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0005","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/v15020588","article-title":"Phage therapy in Germany\u2014Update 2023","volume":"15","author":"Willy","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0006","unstructured":"World Medical Association. WMA Declaration of Helsinki \u2013 ethical principles for medical research involving human participants, https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki\/; 2025 [accessed 25 March 2025]."},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0007","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/v10020064","article-title":"The magistral phage","volume":"10","author":"Pirnay","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0008","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1177\/2168479017694850","article-title":"Overview of FDA\u2019s expanded access program for investigational drugs","volume":"51","author":"Jarow","year":"2017","journal-title":"Ther Innov Regul Sci"},{"issue":"2","key":"10.1016\/j.ijantimicag.2025.107614_bib0009","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1177\/2168479016679214","article-title":"Ten-year experience for the center for drug evaluation and research, part 2: FDA's role in ensuring patient safety","volume":"51","author":"Jarow","year":"2017","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0010","unstructured":"Australian Government | Department of Health and Aged Care \u2014 Therapeutic Goods Administration. Special access scheme (SAS): guidance for health practitioners accessing unapproved therapeutic goods, https:\/\/www.tga.gov.au\/resources\/guidance\/special-access-scheme-sas-guidance-health-practitioners-accessing-unapproved-therapeutic-goods; 2024 [accessed 25 March 2025]."},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0011","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3390\/antibiotics13090795","article-title":"Harnessing bacteriophages to combat antibiotic-resistant infections in Africa: a comprehensive review","volume":"13","author":"Fabiyi","year":"2024","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0012","series-title":"Bacteriophages biol. technol. ther.","first-page":"921","article-title":"Current updates from the long-standing phage research centers in Georgia, Poland, and Russia","author":"Mi\u0119dzybrodzki","year":"2021"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0013","first-page":"35","article-title":"Phages for phage therapy: isolation, characterization, and host range breadth","volume":"12","author":"Hyman","year":"2019","journal-title":"Pharm Basel Switz"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1490737","article-title":"Perception of phage therapy and research across selected professional and social groups in Poland","volume":"13","author":"\u017baczek","year":"2025","journal-title":"Front Public Health"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3947\/ic.2023.0067","article-title":"Phage therapy in Korea: a prescribers\u2019 survey of attitudes amongst Korean infectious diseases specialists towards phage therapy","volume":"56","author":"Lee","year":"2024","journal-title":"Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0016","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1745-6215-11-104","article-title":"Compassionate use of interventions: results of a European clinical research infrastructures network (ECRIN) survey of ten European countries","volume":"11","author":"Whitfield","year":"2010","journal-title":"Trials"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0017","unstructured":"German Center for Infectious Research. Bacteriophages in science and clinical use, https:\/\/www.dzif.de\/en\/event\/bacteriophages-science-and-clinical-use; 2022 [accessed 27 March 2025]."},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0018","unstructured":"Food and Drug Administration. Science and regulation of bacteriophage therapy workshop - 08\/30\/2021, https:\/\/www.fda.gov\/news-events\/fda-meetings-conferences-and-workshops\/science-and-regulation-bacteriophage-therapy-workshop-08302021; 2022 [accessed 27 March 2025]."},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0019","series-title":"National action plan for combating antibiotic-resistant bacteria (CARB) \u2014 2020-2025","article-title":"Federal task force on combating antibiotic-resistant bacteria","year":"2020"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0020","series-title":"Confronting antimicrobial resistance 2024 to 2029","year":"2024"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0021","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1007\/s43441-024-00686-7","article-title":"Insights into early interactions on innovative developments with European regulators","volume":"58","author":"Uster","year":"2024","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0022","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1038\/s41564-024-01705-x","article-title":"Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study","volume":"9","author":"Pirnay","year":"2024","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0023","doi-asserted-by":"crossref","first-page":"ofad221","DOI":"10.1093\/ofid\/ofad221","article-title":"Compassionate use of bacteriophages for failed persistent infections during the first 5 years of the Israeli Phage Therapy Center","volume":"10","author":"Onallah","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0024","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.clinmicnews.2025.01.002","article-title":"Phage therapy to treat unresponsive infections: a primer for the clinical microbiology laboratory staff","volume":"50","author":"Davey-Young","year":"2025","journal-title":"Clin Microbiol Newsl"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0025","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/antibiotics12020417","article-title":"Bacteriophage therapy as an application for bacterial infection in China","volume":"12","author":"Liang","year":"2023","journal-title":"Antibiotics"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0026","unstructured":"Swiss National Science Foundation. Engineered bacteriophages as antbiotic alternatives for treating catheter associated urinary tract infectons (CAUTphage), https:\/\/data.snf.ch\/grants\/grant\/189957; 2020 [accessed 25 March 2025]."},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0027","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-065401","article-title":"Standardised treatment and monitoring protocol to assess safety and tolerability of bacteriophage therapy for adult and paediatric patients (STAMP study): protocol for an open-label, single-arm trial","volume":"12","author":"Khatami","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0028","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1473-3099(18)30482-1","article-title":"Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1\/2 trial","volume":"19","author":"Jault","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101143","article-title":"Revolutionising infection control: building the next generation of phage banks","volume":"77","author":"Wahid","year":"2024","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114438","article-title":"Rationalisation of the purification process for a phage active pharmaceutical ingredient","volume":"203","author":"Lapras","year":"2024","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0031","unstructured":"Federal Agency for Medicines and Health Products. Survey on the therapeutic use eof bacteriophages: summary of the responses Pharmaceutical Committee 07\/11\/2019, https:\/\/health.ec.europa.eu\/document\/download\/0d1d3309-3e4e-4a77-a5ee-00b2fb8d5213_en?filename=pharm779a_sr-bacteriophages_en.pdf&prefLang=de; 2019 [accessed 25 March 2025]."},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0032","series-title":"Proposal for a directive on the union code relating to medicinal products for human use","year":"2023"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0033","unstructured":"European Medicines Agency, Committee for Veterinary Medicinal Products. Guideline on quality, safety, and efficacy of veterinary medicinal products specifically designed for phage therapy. EMA\/CVMP\/NTWP\/32862\/2022 (2023)."},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0034","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s00005-012-0175-0","article-title":"Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine","volume":"60","author":"Verbeken","year":"2012","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0035","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3390\/v16030443","article-title":"The medicinal phage\u2014Regulatory roadmap for phage therapy under EU pharmaceutical legislation","volume":"16","author":"Faltus","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0036","unstructured":"European Pharmacopeia Commission. Phage therapy medicinal products, Ph. Eur. 5.31, adopted 19-20 Mar. 2024, pre-published on EDQM website."},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0037","unstructured":"AWMF Leitlinien. S2k-Leitlinie Personalisierte Bakteriophagn-Therapie in Deutschland, https:\/\/register.awmf.org\/de\/leitlinien\/detail\/092-003; 2023 [accessed 25 March 25, 2025]."},{"key":"10.1016\/j.ijantimicag.2025.107614_bib0038","doi-asserted-by":"crossref","DOI":"10.52504\/001c.117696","article-title":"A way forward for phage therapy in the United States","volume":"8","author":"Swenson","year":"2024","journal-title":"Georget Med Rev"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925001694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857925001694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T23:09:29Z","timestamp":1775516969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857925001694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0924857925001694"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107614","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cross-border dialogue: An international survey of regulators on phage therapy","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107614"}}